LS60 Stock Chart & Stats
€0.13
<€0.01(3.23%)
At close: 4:00 PM EDT
€0.13
<€0.01(3.23%)
Day’s Range― - ―
52-Week Range€0.12 - €1.15
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€8.97M
Enterprise Value€100.00
Total Cash (Recent Filing)€3.87M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding51,939,323
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€2.83M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest risks, giving management flexibility to prioritize commercialization or R&D. Over months this improves solvency and lowers fixed financing costs, providing runway to execute a turnaround without near-term debt obligations.
Installed-base Recurring RevenueThe platform-plus-consumables model creates durable recurring revenue once systems are installed. Consumables and service provide higher-margin, repeatable sales and customer stickiness, supporting steady revenue per installed site and improving lifetime customer value as adoption grows.
Niche, Image-guided Minimally Invasive TherapyCLS operates in a structural growth segment: minimally invasive, image-guided oncology therapies. Specialized technology tied to imaging modalities creates higher technical barriers and clinical switching costs, supporting a defendable niche and potential adoption tailwinds from broader minimally invasive procedure trends.
Bears Say
Declining Revenue And Negative MarginsSustained revenue decline and a shift to negative gross margins indicate persistent under-absorption of fixed costs, pricing or mix pressure, and weak demand. These dynamics make achieving sustainable profitability difficult without durable volume recovery or structural cost reductions.
Material Negative Cash FlowChronic negative operating and free cash flow create ongoing cash burn, forcing dependence on external financing. Over months this constrains investments in sales, clinical evidence, and product development, risks dilution from equity raises, and limits the company’s ability to scale commercial operations.
Asset Contraction And Poor Capital ReturnsDeclining asset base plus negative ROE signal shrinking operational scale and inefficient capital deployment. Persistent losses erode reinvestment capacity, making it harder to rebuild commercial footprint or fund clinical programs, prolonging recovery timelines absent a clear profitability path.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.12 and its highest was €1.15 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €8.97M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is Nov 13, 2026 which is in 102 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Jul 17, 2026. The company reported -€0.035 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 51,939,323 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.734%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―